Characterization of a genetic mouse model of lung cancer: A promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers

BMC Genomics

Volumn 15, Issue , 2014, Pages

  Riccardo, Federica ^a   Arigoni, Maddalena ^a   Buson, Genny ^b   Zago, Elisa ^b   Iezzi, Manuela ^c   Longo, Dario Livio ^a   Carrara, Matteo ^a   Fiore, Alessandra ^a   Nuzzo, Simona ^d   Bicciato, Silvio ^d   Nanni, Patrizia ^e   Landuzzi, Lorena ^f   Cavallo, Federica ^a   Calogero, Raffaele ^a   Quaglino, Elena ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OSTEOPONTIN; SPP1 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; GENE INACTIVATION; GENETIC ASSOCIATION; LIMIT OF QUANTITATION; MALE; METASTASIS POTENTIAL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PROTEIN SECRETION; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RAS; PROGNOSIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; GENES, RAS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; OSTEOPONTIN; PROGNOSIS; TRANSCRIPTOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84925883745     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-S3-S1     Document Type: Article

References (54)

1. Lovly CM, Carbone DP: Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol 2011, 8(2):68-70.
2. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Lozano G, et al: Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 2009, 4(4): e5401.
3. Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J, Gridelli C: Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009, 45(14):2473-2487.
4. Dempke WC, Suto T, Reck M: Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67(3):257-274.
5. Greenberg AK, Lee MS: Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007, 13(4):249-255.
6. Sung HJ, Cho JY: Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008, 41(9):615-625.
7. Sudhindra A, Ochoa R, Santos ES: Biomarkers, Prediction, and Prognosis in Non-Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clin Lung Cancer 2011.
8. Cavallo F, Calogero RA, Forni G: Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007, 7(9):707-713.
9. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL: 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011, 60(3):319-326.
10. Calogero RA, Quaglino E, Saviozzi S, Forni G, Cavallo F: Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike? Cancer Immunol Immunother 2008.
11. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, et al: Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(30):12353-12358.
12. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G: A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 2007, 26(48):6896-6904.
13. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410(6832):1111-1116.
14. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G: High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 2000, 97(8):4174-4179.
15. Lang W, Wang H, Ding L, Xiao L: Cooperation between PKC-alpha and PKC-epsilon in the regulation of JNK activation in human lung cancer cells. Cell Signal 2004, 16(4):457-467.
16. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119(6):847-860.
17. Ueno T, Linder S, Elmberger G: Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003, 88(8):1229-1233.
18. Kontic M, Stojsic J, Kacar-Kukric V, Jekic B, Bunjevacki V: Multidisciplinary approach in diagnosis of lung carcinoma. Experimental oncology 2010, 32(2):111-113.
19. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P: Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clinical pharmacology and therapeutics 2013, 93(3):252-259.
20. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature methods 2008, 5(7):621-628.
21. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM: Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458(7234):97-101.
22. Iyer MK, Chinnaiyan AM, Maher CA: ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011, 27(20):2903-2904.
23. Carrara M, Beccuti M, Lazzarato F, Cavallo F, Cordero F, Donatelli S, Calogero RA: State-of-the-art fusion-finder algorithms sensitivity and specificity. BioMed research international 2013, 2013:340620.
24. Anders S, Reyes A, Huber W: Detecting differential usage of exons from RNA-seq data. Genome research 2012, 22(10):2008-2017.
25. Anders S, Huber W: Differential expression analysis for sequence count data. Genome biology 2010, 11(10):R106.
26. Wittekind C: [2010 TNM system: on the 7th edition of TNM classification of malignant tumors]. Der Pathologe 2010, 31(5):331-332.
27. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, et al: Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. Journal of experimental & clinical cancer research: CR 2012, 31:26.
28. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG: Osteopontin expression in lung cancer. Lung cancer 1996, 15(3):311-323.
29. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH: Tumor-derived granulocyte-macrophage colonystimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer cell 2012, 21(6):822-835.
30. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D: Oncogenic Krasinduced GM-CSF production promotes the development of pancreatic neoplasia. Cancer cell 2012, 21(6):836-847.
31. Mroczko B, Szmitkowski M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B: Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. International journal of colorectal disease 2007, 22(1):33-38.
32. Yaar R, Jones MR, Chen JF, Ravid K: Animal models for the study of adenosine receptor function. Journal of cellular physiology 2005, 202(1):9-20.
33. Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, Gotoh A, Nishizaki T: A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2012, 30(1):210-220.
34. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G: Userguided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006, 31(3):1116-1128.
35. Sanges R, Cordero F, Calogero RA: oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 2007, 23(24):3406-3408.
36. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
37. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193.
38. Conesa A, Nueda MJ, Ferrer A, Talon M: maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 2006, 22(9):1096-1102.
39. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357.
40. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS one 2010, 5(4):e10312.
41. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, et al: Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC bioinformatics 2005, 6:26.
42. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138(1):51-62.
43. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, et al: An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009, 28(31):2773-2783.
44. Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, Schnabel P, Warth A, Poustka A, Sultmann H, et al: Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 2009, 63(1):32-38.
45. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer research 2012, 72(1):100-111.
46. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147(4):759-772.
47. Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, Bicciato S, Battaglia G, Bruno V, Puccetti P, et al: Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nature medicine 2010, 16(8):897-902.
48. Irizarry RA, Ooi SL, Wu Z, Boeke JD: Use of mixture models in a microarray-based screening procedure for detecting differentially represented yeast mutants. Statistical applications in genetics and molecular biology 2003, 2:Article1.
49. Andersen PK, Borch-Johnsen K, Deckert T, Green A, Hougaard P, Keiding N, Kreiner S: A Cox regression model for the relative mortality and its application to diabetes mellitus survival data. Biometrics 1985, 41(4):921-932.
50. Harrington DP FT: A class of rank test procedures for censored survival data. Biometrika 1982, 69:553-566.
51. Thomsen HS, Dorph S: Interventional uroradiology today. Annals of medicine 1992, 24(3):167-169.
52. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature medicine 2008, 14(8):822-827.
53. Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y, et al: Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma. PloS one 2012, 7(9):e43923.
54. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010, 28(29):4417-4424.